Abstract:(a) The etiology of sarcopenia encompasses various factors that synergistically contribute to age‐related damages, leading to metabolic dysregulation and subsequent reductions in muscle strength and mass. (b) We integrated transcriptome data from three cohorts of sarcopenia individuals, applying machine learning algorithms to identify metabolic target genes. Subsequent validation in additional muscle datasets confirmed NNMT as a noteworthy metabolic target of sarcopenia with diagnostic potential. Targeted intervention in the NNMT gene may modulate NAD+‐related pathways to improve metabolic damage of muscle tissues. Sarcopenia is a significant geriatric syndrome that involves the loss of skeletal muscle mass and strength. Due to its substantial endocrine role, the metabolic microenvironment of skeletal muscle undergoes changes with age. Examining the pathogenesis of sarcopenia through focusing on metabolic dysregulation could offer insights for developing more effective intervention strategies. In this study, we analyzed the transcriptomics data to identify specific genes involved in the regulation of metabolism in skeletal muscle during the development of sarcopenia. Three machine learning algorithms were employed to screen key target genes exhibiting strong correlations with metabolism, which were further validated using RNA‐sequencing data and publicly accessible datasets. Among them, the metabolic enzyme nicotinamide N‐methyltransferase (NNMT) was elevated in sarcopenia, and predicted sarcopenia with an area under the curve exceeding 0.7, suggesting it as a potential therapeutic target for sarcopenia. As expected, inhibition of NNMT improved the grip strength in aging mice and alleviated age‐related decline in the mass index of the quadriceps femoris muscles and whole‐body lean mass index. Additionally, the NNMTi treatment increased the levels of nicotinamide adenine dinucleotide (NAD+) content, as well as PGC1α and p‐AMPK expression in the muscles of both the D‐galactose‐treated mouse model and naturally aging mouse model. Overall, this work demonstrates NNMT as a promising target for preventing age‐related decline in muscle mass and strength.

Mechanisms of the NAD+ salvage pathway in enhancing skeletal muscle function

NAD+ centric mechanisms and molecular determinants of skeletal muscle disease and aging

NAD+ homeostasis and its role in exercise adaptation: A comprehensive review

A need for NAD+ in muscle development, homeostasis, and aging

Implications of NAD+ boosters in translational medicine

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process

Nicotinamide Protects Against Skeletal Muscle Atrophy in Streptozotocin-Induced Diabetic Mice

Nicotinamide Mononucleotide: A Promising Molecule for Therapy of Diverse Diseases by Targeting NAD Plus Metabolism

Regulation of and challenges in targeting NAD + metabolism

NAD+ repletion improves muscle function in muscular dystrophy and counters global PARylation

NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications

Nicotinamide riboside-A missing piece in the puzzle of exercise therapy for older adults?

Implications of altered NAD metabolism in metabolic disorders

NAD+ Repletion Improves Mitochondrial and Stem Cell Function and Enhances Life Span in Mice

Identification of nicotinamide N‐methyltransferase as a promising therapeutic target for sarcopenia

Regular exercise effectively protects against the aging-associated decline in skeletal muscle NAD content

NAD+ boosting reduces age-associated amyloidosis and restores mitochondrial homeostasis in muscle

Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice

Nicotinamide and pyridoxine stimulate muscle stem cell expansion and enhance regenerative capacity during aging